Similar Items: Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A Multicenter, Single-Arm, Phase Ib Clinical Trial
- Neuromyelitis optica spectrum disorders with aquaporin-4 antibodies in patients with systemic rheumatic diseases
- Efficacy of Ravulizumab During the Acute Phase of Neuromyelitis Optica Spectrum Disorder
- AQP4-IgG Dynamics and Exploratory Assessment of SERA-3 in Neuromyelitis Optica Spectrum Disorder Treated with Satralizumab
- Integrated Blood Inflammatory Ratios and Cerebrospinal Fluid Blood‒Brain Barrier Dysfunction Predict Relapse Risk in Neuromyelitis Optica Spectrum Disorder
- Comparative Evaluation of Rituximab Versus Approved Therapies in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Network Meta-analysis
- ESTELA‐Study: Long‐Term Effectiveness and Safety of Anti‐Calcitonin Gene‐Related Peptide Monoclonal Antibodies in Real‐World Clinical Practice